Wednesday, November 28, 2007

Suven Life Sciences gets two European patents

India-based Suven Life Sciences Ltd said the European Patent Office has granted patents for two of Suven's compounds (EP1523486 B1 & EP1581538 B1) TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, aimed at treating cognitive impairments associated with neurodegenerative disorders like Alzheimer's, Parkinson's disease and schizophrenia.

The compounds are being developed as therapeutic agents and the patents are valid until June 2022, the company said in a filing to India's National Stock Exchange.

No comments:

Post a Comment